Efficacy of Ondansetron (Gr 38032F) and the Role of Serotonin in Cisplatin-Induced Nausea and Vomiting
- 22 March 1990
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 322 (12) , 810-816
- https://doi.org/10.1056/nejm199003223221204
Abstract
We compared the efficacy and safety of ondansetron (GR 38032F), a selective antagonist of serotonin S3 receptors, with that of placebo in controlling the nausea and vomiting induced by cisplatin treatment in 28 patients with cancer. The patients received either three intravenous doses of ondansetron (0.15 mg per kilogram of body weight) or normal saline (placebo) at four-hour intervals, beginning 30 minutes before the administration of cisplatin.This publication has 34 references indexed in Scilit:
- Do Humoral Factors Mediate Cancer Chemotherapy4Nduced Emesis?Drug Metabolism Reviews, 1989
- Neuropharmacology of emesis induced by anti-cancer therapyTrends in Pharmacological Sciences, 1988
- 5-HT3 receptors and cytotoxic drug-induced vomitingTrends in Pharmacological Sciences, 1987
- MetoclopramideDrugs, 1983
- Review of Cannabinoids and their Antiemetic EffectivenessDrugs, 1983
- The Pharmacology and Clinical Effectiveness of Phenothiazines and Related Drugs for Managing Chemotherapy-induced EmesisDrugs, 1983
- Neuropharmacology of Chemotherapy-induced EmesisDrugs, 1983
- Nausea and Vomiting as Major Complications of Cancer ChemotherapyDrugs, 1983
- Emesis as a Critical Problem in ChemotherapyNew England Journal of Medicine, 1981
- Antiemetic Efficacy of High-Dose Metoclopramide: Randomized Trials with Placebo and Prochlorperazine in Patients with Chemotherapy-Induced Nausea and VomitingNew England Journal of Medicine, 1981